How to monitor disease progression in ATTR amyloid cardiomyopathy: Implications for clinical practice and trial design - PubMed
11 hours ago
- #Disease Progression
- #ATTR-CM
- #Cardiac Biomarkers
- ATTR amyloid cardiomyopathy (ATTR-CM) is no longer considered a rare and fatal condition due to new therapies.
- Monitoring disease progression is crucial for clinical decision-making and personalized treatment strategies.
- Key indicators include worsening heart failure symptoms, diuretic use, 6-minute walk test decline, and cardiac biomarkers.
- An integrated, multiparametric approach is recommended for precise disease assessment.
- Novel therapies aim to clear amyloid deposits, offering potential for disease regression.
- Future clinical trials may use disease progression criteria as surrogate endpoints.